Form 4: Amylyx Pharmaceuticals Co-CEO Justin B. Klee Reports Sale of Shares for Tax Obligations

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, reports the sale of shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Justin B. Klee, Co-Chief Executive Officer of Amylyx Pharmaceuticals, reported a transaction on March 3, 2025.
• Klee sold 4,595 shares of Common Stock to cover tax withholding obligations related to the vesting of restricted stock units.
• The shares were sold at a weighted average price of $3.152, with individual prices ranging from $3.10 to $3.19.
• Following the transaction, Klee beneficially owns 3,196,648 shares of Amylyx Pharmaceuticals.
• The sale was automatic and not at the discretion of Klee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports a routine transaction to cover tax obligations. It doesn't inherently indicate positive or negative performance for the company.

Industry Context

Form 4 filings are a routine part of the stock market, providing transparency into the transactions of company insiders. This particular filing indicates a sale of shares to cover tax obligations, which is a common practice.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates